Grace Therapeutics (GRCE) Times Interest Earned (2019 - 2026)
Grace Therapeutics (GRCE) posted Times Interest Earned of -$1.17 for Q1 2026, up 44.26% sequentially from -$2.11 in Q4 2025, and up 99.11% YoY from -$0.59 in Q1 2025.
Grace Therapeutics (GRCE) Times Interest Earned (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Times Interest Earned for 7 years, with the latest figure at -$1.17 in Q1 2026.
- Quarterly Times Interest Earned rose 99.11% year-over-year to -$1.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.32 (up 99.38% YoY) and the FY2026 annual result came in at -$0.21, up 37.75% from the prior year.
- Times Interest Earned improved to -$1.17 in Q1 2026 per GRCE's latest filing, from -$2.11 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.1 in Q1 2022 and troughed at -$2092.0 in Q3 2023.
- A 5-year average of -$224.0 and a median of -$16.43 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned soared 99.61% in 2022, then sank 398426.02% in 2023.
- Over 5 years, Times Interest Earned stood at -$0.1 in 2022, then tumbled by 122000.69% to -$126.79 in 2023, then surged by 96.62% to -$4.28 in 2024, then soared by 50.78% to -$2.11 in 2025, then jumped by 44.26% to -$1.17 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$1.17, -$2.11, and -$4.22 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 1.42 |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -180.88 |
| Mar 31, 2026 | -1.17 |
| Dec 31, 2025 | -2.11 |
| Sep 30, 2025 | -4.22 |
| Jun 30, 2025 | -5.20 |
| Mar 31, 2025 | -132.63 |
| Dec 31, 2024 | -4.28 |
| Sep 30, 2024 | -16.43 |
| Mar 31, 2024 | -58.27 |
| Dec 31, 2023 | -126.79 |
| Sep 30, 2023 | -2,092.00 |
| Jun 30, 2023 | -54.99 |
| Mar 31, 2023 | -413.84 |
| Mar 31, 2022 | -0.10 |
| Mar 31, 2021 | -26.74 |
| Jun 30, 2019 | -266.87 |